Jasper Therapeutics, Inc. has announced a 1-for-30 reverse stock split of its voting common stock, which will be effective at 12:01 a.m. Eastern Time on November 6, 2026. The company's stock is expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market at the market open on the same day. This action will significantly reduce the number of shares outstanding but will not change the total number of authorized shares.
Key Details
- Ratio: Every thirty shares of pre-split common stock will be combined into one share of post-split common stock.
- Effective Date: The reverse stock split becomes effective on November 6, 2026, with split-adjusted trading beginning at the market open.
- Impact on Shares: The number of issued and outstanding shares will decrease from approximately 33.3 million to approximately 1.1 million. The number of authorized shares remains unchanged at 490 million.
- Trading Information: The stock will continue to trade under the ticker "JSPR" but will have a new CUSIP number of 471871301.
- Fractional Shares: No fractional shares will be issued. Stockholders will receive cash in lieu of any fractional shares based on the closing price on November 5, 2026.